Dextran-catechin conjugate: A potential treatment against the pancreatic ductal adenocarcinoma

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2601-2614

  Vittorio, Orazio ^a   Cirillo, Giuseppe ^b   Iemma, Francesca ^b   Di Turi, Giovanni ^c   Jacchetti, Emanuela ^a   Curcio, Michele ^d   Barbuti, Serena ^d   Funel, Niccola ^c   Parisi, Ortensia Ilaria ^b   Puoci, Francesco ^b   Picci, Nevio ^b  

^a ISTITUTO NANOSCIENZE CNR   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d CISANELLO HOSPITAL   (Italy)

Author keywords

Anticancer activity; Antioxidant polymer conjugates; Catechin; Pancreatic ductal adenocarcinoma; Polymeric drugs

Indexed keywords

CATECHIN; DEXTRAN; NESTIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CARCINOMA CELL; CELL KILLING; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG MIXTURE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, PANCREATIC DUCTAL; CATECHIN; CELL LINE, TUMOR; CHROMATOGRAPHY, GEL; DEXTRANS; DNA PRIMERS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84866722504     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0790-9     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Baghurst PA, Mc Michael AJ, Slavotinek AH, Baghurst KI, Boyle P, Walker AM. A case-control study of diet and cancer of the pancreas. Am J Epidemiol. 1991;134:167-79.
3. Berrington de Gonzalez A, Sweetland S, Spencer E. A metaanalysis of obesity and the risk of pancreatic cancer. Br J Cancer. 2000;89:519-23.
4. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: A meta-analysis. JAMA, J Am Med Assoc. 1995;273:1605-9.
5. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049-57.
6. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J ClinOncol. 1997;15:2403-13.
7. Neuhaus P, Oettle H, Post S, Gellert K, Ridwelski K, Schramm H, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. Proc Ann Meet Am Soc Clin Oncol. 2005;4013.
8. Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer. 2002;95:941-5.
9. Oettle H, Arning M, Pelzer U, Arnold D, Stroszczynski C, Langrehr J, et al. A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol. 2000;11:1267-72.
10. Kurtz J, Kohser F, Negrier S, Trillet Lenoir V, Walter S, Limacher J, et al. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepato-Gastroenterology. 2000;47:1450-3.
11. Heinemann V. Gemcitabine: Progress in the treatment of pancreatic cancer. Oncology. 2001;60:8-18.
12. Kornek G, Potter R, Selzer E, Schratter A, Pur HU, Rogy M, et al. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys. 2001;49:665-71.
13. Yang CS, Chung JY, Yang G, Chhabra SK, Lee MJ. Tea and tea polyphenols in cancer prevention. J Nutr. 2000;130:472S-8S.
14. Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer. 2001;84:844-50.
15. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003;63:8118-21.
16. Pellecchia M, Reed JC. Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: New avenues for cancer chemoprevention and chemotherapy. Curr Pharm Des. 2004;10:1387-98.
17. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688-701.
18. Vicent MJ, Duncan R. Polymer conjugates: Nanosized medicines for treating cancer. Trends Biotechnol. 2006;24:39-47.
19. Greco F, VicentMJ. Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Delivery Rev. 2009;61:1203-13.
20. Maeda H. Polymer conjugated macromolecular drugs for tumorspecific targeting. In: Domb AJ, editor. Polymeric site-specific pharmacotherapy. New York: John Wiley and Sons; 1994. p. 95-116.
21. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999;5:83-94.
22. Meerum Terwogt JM, Bokkel Huinink WW, Schellens JHM, Schot M, Mandjes I, Zurlo M, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer conjugated prodrug of paclitaxel. Anti-Cancer Drug Des. 2001;12:315-23.
23. Minko T, Kopeéková P, Pozharov V, Kopeéek J. HPMA copolymer bound Adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release. 1998;54:223-33.
24. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules. 2000;1:208-18.
25. Spizzirri UG, Iemma F, Puoci F, Cirillo G, Curcio M, Parisi OI, et al. Synthesis of antioxidant polymers by grafting of gallic acid and catechin on gelatin. Biomacromolecules. 2009;10:1923-30.
26. Cirillo G, Puoci F, Iemma F, CurcioM, ParisiOI, Spizzirri UG, et al. Starch-quercetin conjugate by radical grafting: Synthesis and biological characterization. Pharm Dev Technol. 2009.doi:10.3109/10837450.2010.546413.
27. Cirillo G, Kraemer K, Fuessel S, Puoci F, Curcio M, Spizzirri UG, et al. Biological activity of a gallic acid-gelatin conjugate. Biomacromolecules. 2010;11:3309-15.
28. Shrivastava PK, Shrivastava SK. Dextran polysaccharides: Successful macromolecular carrier for drug delivery. Int J Pharm Sci. 2009;1:353-68.
29. Garnett MC. Targeted drug conjugates: Principles and progress. Adv Drug Delivery Rev. 2001;53:171-216.
30. Cho HJ, Chong S, Chung SJ, Shim CK, Kim DD. Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: Its application for head and neck cancer treatment. Pharm Res. 2011. doi:10.1007/s11095-011-0642-z.
31. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629-37.
32. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Büchler MW, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3:1309-16.
33. Wang H, Helliwell K, You X. Isocratic elution system for the determination of catechins, caffeine and gallic acid in green tea using HPLC. Food Chem. 2000;68:115-21.
34. Pan Y, Zhu J, Wang H, Zhang X, Zhang Y, He C, et al. Antioxidant activity of ethanolic extract of Cortex fraxini and use in peanut oil. Food Chem. 2007;103:913-8.
35. Waterman KC, Adami RC, Alsante KM, Hong J, Landis MS, Lombardo F, et al. Hydrolysis in pharmaceutical formulations. Pharm Dev Technol. 2002;7:1-32.
36. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun. 2003;301:1038-44.
37. James R, Warburton S. Hemocytometer cell counts and viability studies: Cell quantification. In: Doyle A, Grifith JB, editors. Cell and tissue culture: Laboratory procedures in biotechnology. London: John Wiley; 1999. p. 57-61.
38. Tomonori N, Keisuke I, Yasuo I. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res. 2005;11:6040-9.
39. Diaz G, Liu S, Isola R, Diana A, Falchi AM. Mitochondrial localization of reactive oxygen species by dihydrofluorescein probes. Histochem Cell Biol. 2003;120:319-25.
40. Uyama H, Maruichi N, Tonami H, Kobayashi S. Peroxidasecatalyzed oxidative polymerization of bisphenols. Biomacromolecules. 2002;3:187-93.
41. Quatresooz P, Pierard GE, Pierard-Franchimont C, Arrese JE, Blaise G, Bourguignon R, et al. Molecular pathways supporting the proliferation staging of malignant melanoma. Int J Mol Med. 2009;24:295-301.
42. Teo BKK, Goh SH, Kustandi TS, Loh WW, Low HY, Yim EKF. The effect of micro and nanotopography on endocytosis in drug and gene delivery systems. Biomaterials. 2011;32:9866-75.